Compass Therapeutics, Inc. (CMPX) stock
CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.05 (-5.63%)
Close on Nov 13, 2026Market cap $139.35MP/E –Yield –
Compass Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Compass Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$94.07M. For fiscal 2025 it was -$72.84M. The highest annual figure on record is -$27.81M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$72.84M | – |
| FY2024 | Dec 31, 2024 | -$56.63M | – |
| FY2023 | Dec 31, 2023 | -$50.36M | – |
| FY2022 | Dec 31, 2022 | -$41.66M | – |
| FY2021 | Dec 31, 2021 | -$81.88M | – |
| FY2020 | Dec 31, 2020 | -$27.81M | – |
| FY2019 | Dec 31, 2019 | -$34.05M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$28.80M | – |
| Q2 FY2026 | Jun 30, 2026 | -$26.98M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.30M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.99M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.82M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.07M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.97M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.57M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.24M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.05M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.39M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.93M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.60M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.18M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.00M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.85M | – |
| Q2 FY2021 | Jun 30, 2021 | -$55.69M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.34M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.95M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.96M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.07M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.83M | – |
| Q2 FY2019 | Sep 30, 2019 | -$8.38M | – |
| Q1 FY2019 | Jun 30, 2019 | -$19.27M | – |
| Q2 FY2018 | Sep 30, 2018 | -$7.79K | – |
See a number that looks wrong?